Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.41 |
| ▸ | PIK3R2 | O00459 | 3/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2711847 | 0.92 | PIK3CA (0.42) | PIK3CAPIK3R2CCNT1CCNA2CDK2 | |
| SCHEMBL2713674 | 0.92 | PIK3CA (0.42) | PIK3CAPIK3R2CCNT1CCNA2CDK2 | |
| SCHEMBL2713606 | 0.89 | PIK3CA (0.45) | PIK3CAPIK3CDTGFBR1PIK3R2PIK3CB | |
| SCHEMBL2713720 | 0.88 | PIK3R2 (0.49) | PIK3CAPIK3CDTGFBR1PIK3R2PIK3CB | |
| SCHEMBL2712984 | 0.88 | PIK3R2 (0.49) | PIK3CAPIK3CDTGFBR1PIK3R2PIK3CB | |
| SCHEMBL2711238 | 0.87 | PIK3CD (0.48) | PIK3CAPIK3CDPIK3R2PIK3CBPIK3CG | |
| SCHEMBL2727246 | 0.84 | PIK3CA (0.56) | PIK3CAPIK3CDTGFBR1PIK3CBPIK3CG | |
| SCHEMBL249196 | 0.82 | PIK3CA (0.40) | PIK3CAPIK3CDTGFBR1PIK3R2PIK3CB | |
| SCHEMBL248197 | 0.80 | PIK3CD (0.41) | PIK3CAPIK3CDPIK3R2PIK3CBPIK3CG | |
| SCHEMBL2712362 | 0.80 | PIK3R2 (0.46) | PIK3CAPIK3R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | PIK3CA 29/4885PIK3CD 14/4885TGFBR1 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.